ReviewDrugs2015
Targeting interferons in systemic lupus erythematosus: current and future prospects.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 63 citations in OpenAlex.
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2017Trial
- Focus on Interferon Signature in Cutaneous Lupus Erythematosus: Novel Therapies From Better Understanding of the Pathogenesis.Journal of immunology research · 2025Review
- Genetic polymorphisms in genes involved in the type I interferon system (STAT4 and IRF5): association with Asian SLE patients.Clinical rheumatology · 2024Review
- Interferon Inhibition in SLE: From Bench to Bedside.Mediterranean journal of rheumatology · 2024Review
- Learning single-cell perturbation responses using neural optimal transport.Nature methods · 2023Article
- The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.Nature reviews. Nephrology · 2022Review
- IFN-α blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health.JCI insight · 2022Article
- Characterization of drug binding with alphaJournal of chromatography. A · 2021Article
- Sustained high expression of multiple APOBEC3 cytidine deaminases in systemic lupus erythematosus.Scientific reports · 2021Article
- Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.International journal of molecular sciences · 2020Review
- Type I interferon antagonists in clinical development for lupus.Expert opinion on investigational drugs · 2020Review
- Article
- Biologic therapy in the idiopathic inflammatory myopathies.Rheumatology international · 2020Review
- Identification of Imidazo[1,2-ACS medicinal chemistry letters · 2019Article
- Immune response patterns in non-communicable inflammatory skin diseases.Journal of the European Academy of Dermatology and Venereology : JEADV · 2018Review
- [Anifrolumab in systemic lupus erythematosus].Zeitschrift fur Rheumatologie · 2018Article
- Cytokine and autoantibody clusters interaction in systemic lupus erythematosus.Journal of translational medicine · 2017Article
- Studies of drug interactions with alphaJournal of chromatography. A · 2017Article
- Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Rheumatology (Oxford, England) · 2017Review
- Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown aetiology that can be debilitating and life threatening. As new insights are gained into the underlying pathology of SLE, there have been an unprecedented number of new agents under development to treat the disease via a diverse range of targets. One such class of emerging agents target interferon (IFN) signalling. In this article, we review the preclinical evidence that the inhibition of the secretion and downstream effectors of both IFN-α and IFN-γ may be effective for the treatment of SLE. The primary agents that are currently in clinical development to treat SLE via the targeting of interferon pathways are monoclonal neutralising antibodies (Mab) that bind to and neutralise IFN-γ (AMG 811), IFN-α (sifalimumab, rontalizumab and AGS-009) or its receptor (anifrolumab), and IFN-α kinoid, which is a drug composed of inactivated IFN-α molecules coupled to the keyhole limpet haemocyanin protein. Phase I and II trials have demonstrated acceptable short-term safety with no increase in severe viral infections or reactivation, favourable pharmacokinetic profiles and an inhibition of IFN-associated gene overexpression; however, the impact of these drugs on disease activity must still be assessed in phase III clinical trials. This review concludes with a summary of the challenges that are inherent to this approach to managing SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.